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Impact of a PCR point of care test for
influenza A/B on an acute medical unit in a
large UK teaching hospital: results of an
observational, pre and post intervention
study
Mark I. Garvey1,2* , Martyn A. C. Wilkinson1, Craig W. Bradley3, Martin Biggs1, Vinay Reddy-Kolanu1, Husam Osman1,
Sarah Carmalt1 and Elisabeth Holden1
Abstract
Background: Influenza viruses is a leading cause of acute respiratory infection, placing a significant burden on
healthcare. To reduce hospital transmission, patients clinically suspected of having influenza are isolated and offered
empirical antiviral treatment. Here we report the use of a point of care test (POCT) for influenza viruses in an acute
medical unit (AMU) at Queen Elizabeth Hospital Birmingham for patients presenting with influenza-like illness.
Methods: A PCR POCT was installed on AMU in Dec 17 – Mar 18 (period 2) and used to test any patient with
influenza-like illness. We conducted an evaluation against influenza virus’s data collected between Dec 16–Mar 17
(period 1) where no POCT was used. Four outcomes were measured: length of stay, oseltamivir utilisation, time to
isolation and in-hospital cases of influenza viruses.
Results: There were 51 confirmed influenza virus cases in period 1 vs 666 in period 2. During period 2, the length
of stay of patients presenting with influenza-like illness (2.4 vs 7.9 days) and time to isolation from receipt of a
positive result (0.09 vs 1.26 days) was significantly shorter. The time to initial receipt of antivirals for patients with
influenza virus was significantly quicker in period 2 (0.59 vs 1.1 days) and the total number of influenza virus cases
identified after 72 h of admission was significantly lower (9% vs 51%).
Discussion: Following introduction of the POCT, there was an increase in appropriately targeted oseltamivir
prescribing, shorter time to isolation, proportionally less post-72-h influenza virus cases and a reduction in length of
stay of patients presenting with influenza-like illness.
Conclusions: Routine use of POCTs for viruses should be introduced into diagnostic pathways for acute respiratory
illness, especially at the front door of hospitals.
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Background
Influenza viruses is a leading cause of acute respiratory
infection. It is responsible for a large burden of disease,
including serious complications in patients with risk fac-
tors such as pregnancy, young children, elderly, or those
with underlying medical conditions [1, 2]. Studies have
shown respiratory viruses are detectable in 40–50% of
hospitalised adults with acute respiratory illness [3, 4].
The case fatality rate of influenza in hospitalised patients
is quoted at 3–8% [3, 5]. Influenza viruses are highly
transmissible within both community and healthcare set-
tings, and places a significant burden on healthcare [1–
3]. Nosocomial influenza virus outbreaks lead to in-
creased bed occupancy and closed wards during winter
months, with significant financial implications [6]. Pre-
vention of influenza virus transmission within healthcare
facilities requires a multipronged approach, including
general precautions such as correct hand hygiene, re-
spiratory etiquette, patient specific contact/droplet pre-
cautions, vaccination of patients and staff, antiviral
treatment or chemoprophylaxis and surveillance of cases
[7, 8]. Rapid detection and implementation of chemo-
prophylaxis within hospitals has been identified as one
of the most important interventions to contain an influ-
enza virus outbreak [9].
Influenza virus testing in the UK is based on clinical
suspicion and the use of laboratory-based PCR tests [10,
11]. In the UK, laboratory-based PCR turnaround times
range at 24–48 h [10, 12]. One of the mainstays of con-
trolling influenza in healthcare is around timely diagno-
sis [10]. Point of care tests (POCT) can be non-
molecular or molecular-based [13]. POCT for influenza
viruses have been previously antigen-based, however
lack sensitivity [13]. More recently, rapid molecular tests
are available and broadly equivalent to laboratory-based
PCR [13]. A major benefit of POCT is the rapidity of re-
sults, which is important to guide clinical management
[13]. They can also guide infection control measures to
optimise patient allocation and bed utilisation within the
hospital, reduce nosocomial transmission of respiratory
viruses and provide an earlier diagnosis of viral respira-
tory tract infections [13]. An influenza virus POCT, spe-
cifically a Cepheid GeneXpert, was used in the acute
medical unit (AMU) at Queen Elizabeth Hospital Bir-
mingham (QEHB), part of University Hospitals Birming-
ham (UHB) NHS Foundation Trust, during the 2017/18
influenza season. After the end of the influenza season, a
service evaluation was conducted to assess the impact of
the POCT on patient care and infection control. The re-
sults were compared to the previous influenza season
(2016/17), when no POCT was used. Outcomes included
rates of healthcare-associated influenza virus, utilisation
of oseltamivir, length of stay and achievement of respira-
tory isolation.
Materials and methods
Setting
QEHB is a major UK teaching hospital, providing clin-
ical services to nearly 1 million patients every year. The
AMU at QEHB consists of an Emergency Department
and a Clinical Decision Unit with a combined total of 88
beds.
Time period
The evaluation was conducted at QEHB in patients pre-
senting with influenza-like illness during two time pe-
riods (period 1 Dec 16–Mar 17 vs period 2 Dec 17-Mar
18). A PCR POCT (Cepheid, USA; GeneXpert) was in-
stalled on AMU in period 2 and used to test any patients
with influenza-like illness. In period 1 a laboratory-based
PCR (Cepheid, USA; GeneXpert) was used to test for in-
fluenza A, influenza B, respiratory syncytial virus (RSV).
The GeneXpert was used as previously described and
tests for Influenza A/B and RSV [14]. The PCR POCT
was housed within a store room within AMU, easily ac-
cessible by all staff on AMU. The staff that used the
POCT were the ward nurses, trained by the in house
POCT team. The POCT test was validated and quality
control checked by the POCT team comparing to the in
house laboratory based PCR test.
Outcomes
Four outcomes were used to assess the impact of the
POCT: length of stay, drug utilisation (oseltamivir pre-
scription), time to isolation after receipt of a positive re-
sult and healthcare associated influenza virus cases.
Data collection
The Infection Prevention and Control team kept a data-
base of all positive respiratory virus results between Sept
2016 to June 2018. The database was cross referenced
against PCR data extracted from the Laboratory Infor-
mation Management system and the POCT used on
AMU to ensure all positive respiratory virus results were
picked up. The database was populated from QEHBs Pa-
tient Information and Communication System with: pa-
tient details, date of isolation, date of the influenza virus
result, date of admission and start date of the oseltamivir
prescription. Community-acquired influenza infection
was defined as influenza virus detection by PCR < 72 h
after admission, for healthcare-associated influenza in-
fection this was defined as influenza virus detection by
PCR ≥ 72 h after admission [3]. This standard definition
is based upon the usual in-vivo incubation period for in-
fluenza being 1–3 days and a practical solution to the
fact that information pertaining to symptom onset was
not readily available [3, 15, 16].
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Statistical analysis
All admission and discharge dates were retrieved from
the electronic admission records system by the hospital
informatics service. Non–parametric statistical tests
were used to analyse the effect of the POCT on length
of stay. Using length of stay as the response variable, pa-
tients admitted to QEHB during period 1 (2016/17) and
period 2 (2017/18) were divided into different groups
based on the clinical coding of patients on admission
(Table 1). The clinical coding of patients admitted to
QEHB who had confirmed and/or suspected influenza
fell into two categories; lower respiratory tract infection
and influenza, and influenza alone (Table 1). To note all
patients presenting with acute respiratory tract infection
would have been tested for Influenza infection. A
Kruskal-Wallis test was used to see whether there was
evidence of disparity in the median length of stay for the
different groups. A pairwise comparisons amongst the
groups, looking for evidence that the medians were dis-
parate was undertaken. The tests used here were Mann-
Whitney U tests, with Holm’s correction for multiple
comparisons.
A chi-squared test was used to check for equality of
proportions between the numbers of healthcare-
associated cases of influenza virus in period 1 and 2. A
non-parametric test was used measure the difference in
means between the time required to isolate patients and
the time to prescribe oseltamivir in period 1 and 2 as
the data was non-normal. As such a Mann-Whitney U
test with continuity correction was used.
Ethics
No IRB approval was needed (exemption).
Results
QEHB influenza seasons
In period 2 there were 256 laboratory confirmed cases of
influenza A and 408 laboratory cases of influenza B, of
which two patients were dually infected with both vi-
ruses. This was significantly more than previous years,
where QEHB saw 51 cases in 2016/17 (period 1), 71
cases in 2015/16 and 155 cases in 2014/15.
Length of stay
Patients with confirmed/suspected influenza in periods 1
and 2 were divided into different groups based on the
clinical coding reason for admission. The categories
were lower respiratory tract infection and influenza, and
influenza alone (Table 1). A Kruskal-Wallis test was
used, to see whether there was evidence of disparity in
the median length of stay data for the different groups.
The p < 0.001 (p = 2.20 × 10− 16) provided strong evi-
dence that the medians differ. A pairwise comparison
was performed amongst the groups, looking for evidence
that the medians were disparate. A Mann-Whitney U
test, with Holm’s correction for multiple comparisons
was used on the groups (Table 2). Patients coded with
influenza alone in period 1 (2016/17) had a median
length of stay was 206.75 h as compared to period 2,
(2017/18) where the median length of stay of 89.94 h
(Fig. 1). This difference was highly significant p < 0.001
(p = 1.51 × 10− 5).
Time to isolation
Of the 666 patients with either Influenza A or B in
period 2, the mean time to isolation after receipt of a
positive result was 0.09 of a day (median 0 days) (Fig. 2).
Compared to period 1 this was shorter, where the mean
time to isolation was 1.25 days (median 1 day) (Fig. 2). A
Mann-Whitney U test was used to measure the differ-
ence in means between period 1 and 2. The p < 0.001
(p = 2.2 × 10− 16) provided strong evidence that the
means differ.
Administration of antivirals
The time to initial receipt of antivirals for patients with
influenza virus was quicker in period 1, with a median of
0.6 days; compared to period 1, with a median of 1.06
days (Fig. 3). A Mann Whitney U test with continuity
correction was used measure the difference in means be-
tween period 1 and 2 (Fig. 3). A p < 0.001 (p = 1.058 ×
10− 7) provided strong evidence that the means differ.
Rates of healthcare associated influenza virus
In period 1 25 of the 51 cases (49%) were identified after
72 h of admission. Fewer healthcare associated influenza
Table 1 Length of stay data in period 1 (2016/17) and period 2 (2017/18) from patients admitted to QEHB with influenza-like illness.
All patients with confirmed influenza in periods 1 and 2 fell within these admission coding descriptions
Group Period Year Number of patients Median LoS (days) Median LoS (hours)
A - LRTI and Influenza 1 2016/17 10 9.01 216.18
B - Influenza 1 2016/17 49 8.61 206.75
C - LRTI and Influenza 2 2017/18 24 5.16 123.83
D - Influenza 2 2017/18 642 3.75 89.94
Key: LRTI, lower respiratory tract infections; LoS, length of stay
Note: All admission and discharge dates were retrieved from the electronic admission records system by the hospital informatics service. All patients with
influenza during period 1 and 2 fell into the admission coding LRTI and Influenza or Influenza alone
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virus were identified in period 2 with 64 of the 666 cases
(9%) identified after 72 h of admission. A chi squared
test was used to check for equality of proportions be-
tween period 1 and 2. A p < 0.001 (p = 1.184 × 10− 15)
provided very strong evidence that the proportions
differ. The 95% confidence interval for the difference in
the two proportions was (0.2445, 0.5437).
Discussion
Influenza virus is highly transmissible in a healthcare
setting. As such it is recommended that patients clinic-
ally suspected of having influenza are isolated and of-
fered empirical antiviral treatment [1, 2]. Rapid influenza
virus detection and implementation of chemoprophy-
laxis within hospitals has been identified as one of the
most important interventions to contain an outbreak [1].
Recently, Young et al., (2018) discussed the impact of a
POCT for influenza virus in an emergency department
[3]. The POCT was associated with reduced nosocomial
transmission of influenza virus and improved patient
flow [3]. A recent randomised clinical trial showed simi-
lar effects and suggested use of a POCT was associated
with a reduced length of stay as well as improved influ-
enza virus detection and antiviral use [10]. Here, we re-
port our experience of using a POCT in an AMU
looking primarily at four outcomes: length of stay, osel-
tamivir utilisation, time to isolation and in-hospital cases
of influenza virus.
At QEHB, healthcare associated influenza virus cases
of 49% (period 1) were reported in 2016/17 compared to
9% (period 2) in 2017/18. There was strong statistical
Table 2 Statistical comparison of the length of stay data (days)
in period 1 (2016/17) and period 2 (2017/18) of patients
admitted to QEHB with influenza-like illness, using a Mann
Whitney U test, with Holm’s correction for multiple comparisons
Comparison Median 1 Median 2 p-value
D vs C 3.75 5.16 0.183
D vs B 3.75 8.61 1.59 × 10−6
D vs A 3.75 9.01 0.166
C vs B 5.16 8.61 0.535
C vs A 5.16 9.01 0.720
B vs A 8.61 9.01 0.812
Key: A, lower respiratory tract infection and influenza in period 1; B, influenza
in period 1; C, lower respiratory tract infection and influenza in period 2; D,
influenza in period 2
Note: A Kruskal-Wallis test was used on the data, to see whether there was
evidence of disparity in the median length of stay for the different groups.
Next, pairwise comparisons amongst the groups, looking for evidence that the
medians were disparate was performed. The tests used here were Mann-
Whitney U tests, with Holm’s correction for multiple comparisons. The table
displays the results for the comparisons
Fig. 1 Length of stay in days of all patients with confirmed influenza during period 1 and period 2. Note: The white diamonds represent the
mean days of length of stay in period 1 and 2. Red circles represents all patients in period 1. Blue circles represent all patients in period 2
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evidence that the mean number of healthcare associated
influenza virus cases differed between period 2 where
the POCT was used, compared to period 1 where it was
not used. Young et al., (2018) recently demonstrated a
similar result where the rate of healthcare-associated in-
fection per day was lower after the implementation of a
POCT in an emergency department [3]. The number of
healthcare associated influenza virus cases in period 2
when the POCT was introduced in our setting could be
in part due to the POCT. Young et al., (2018) demon-
strates that a POCT enables influenza virus cases to be
identified earlier, thereby allowing for appropriate infec-
tion control precautions such as isolation and antiviral
treatment [3]. In addition, patients presenting with
Fig. 2 Time to isolation in days of all patients with confirmed influenza during period 1 and period 2. Note: The white diamonds represent the
mean days till isolation in period 1 and 2. Red circles represents all patients in period 1. Blue circles represent all patients in period 2
Fig. 3 Time to first dose of oseltamivir (days) in all patients with confirmed influenza during period 1 and period 2. Note: The white diamonds
represent the mean days till first dose of oseltamivir in period 1 and 2. Red circles represents all patients in period 1. Blue circles represent all
patients in period 2
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influenza could be discharged home more quickly,
thereby prevented delayed diagnosis within the health-
care setting and the opportunity for transmission [3, 10].
Similarly in a recent RCT by Brendish et al., (2017) com-
paring the use of a POCT vs an in-house laboratory
method, a reduction in length of stay was observed in
patients testing positive for respiratory viruses [10].
Brendish et al., (2018) also demonstrated rapid turn-
around times using a POCT are associated with higher
rates of early discharge and early discontinuation of anti-
biotics compared to longer turnaround times in adults
with acute respiratory illness [17]. Other reasons for the
results observed in the current study could include the
acuity of the strains of influenza virus, which could po-
tentially have been less virulent. Out of the 666 cases of
influenza viruses reported in period 2, 408 cases were in-
fluenza B, as compared to period 1, where there were
three cases of influenza B. Further work is warranted to
observe whether a POCT does in fact reduce transmis-
sion rates via more timely identification.
The reduction in healthcare-associated influenza virus
cases seen in the current study may result from im-
provements in respiratory isolation. The ability for re-
spiratory isolation in the first five days of admission
when patients are most infectious has been previously
shown to reduce rates of transmission of healthcare-
associated influenza viruses. Time to isolation in period
2 was significantly quicker compared to period 1 in the
current study; the POCT could in part explain these re-
sults. Brendish et al., (2017) demonstrated side room iso-
lation for confirmed respiratory virus infection was more
common when a POCT was used [10]. Similarly to our
study, they demonstrated better use of side rooms when
the POCT was used; with reduced time from admission
to isolation in confirmed influenza virus cases [10]. The
authors concluded that rapid and appropriate assign-
ment of side rooms for patients with respiratory virus in-
fection is hugely important to reduce the risk of
nosocomial transmission to other vulnerable hospitalised
patients [10]. Similar findings would be true at QEHB
where patients with transmissible respiratory viral infec-
tions are isolated (data not shown). When the infection
status is not known, or even considered, patients are not
often isolated. Young et al., (2018) demonstrated that
when a POCT was not used to identify patients with in-
fluenza they were not isolated as often as than those pa-
tients where a POCT was used to diagnose influenza
(21.5% vs 74.8%). Thereby increasing the risk of influ-
enza virus exposure to susceptible patients [3].
In addition to reductions in healthcare associated in-
fluenza virus cases and time to isolation, our study
shows that POCT might be associated with a reduction
in hospital length of stay. The median length of stay of
patients with influenza virus in period 2 was statistically
lower compared to period 1. It is possible that the preva-
lent strain of influenza virus provoked less severe disease
in period 2 than period 1, which could in part explain
the results seen. Brendish et al., (2017) demonstrated a
similar finding in patients with exacerbation of airways
disease [10]. The authors concluded that reduced hos-
pital length of stay was due to earlier discharge in pa-
tients testing positive for respiratory viruses via a POCT
[10]. The reduction in length of stay reported by Brend-
ish et al., (2017) was in the order of 1 day, which equated
to around 200,000 bed days saved, with a cost saving of
£80 million per year [10, 18]. In the current study, the
reduction in length of stay was in the magnitude of 3
days, with a higher proportion of bed days saved and
thus the potential for even greater cost savings. Further
work is warranted to explore the cost savings.
In agreement with prior studies, we found that pre-
scription of oseltamivir increased post-introduction of
an influenza virus POCT (data not shown) [19–21].
Oseltamivir treatment is recommended by UK Public
Health England for all patients hospitalised with influ-
enza [22]. Our study showed a statistically quicker ad-
ministration of oseltamivir in period 2, when a POCT
was used, as compared to period 1. Increased oseltamivir
prescription may have contributed towards a reduction
in healthcare-associated influenza viruses seen at QEHB
by reducing ongoing transmission. Brendish et al., (2017)
showed that a POCT for respiratory viruses leads to an
increased proportion of influenza-positive patients cor-
rectly receiving treatment with neuraminidase inhibitors
and suggested a reduced time to administration of the
first dose [10]. There is much debate on the effectiveness
of oseltamivir, however the literature details the most ef-
fective use is within the first 48 h of symptoms [23]. The
POCT in our setting certainly helped with quicker ad-
ministration of oseltamivir. Further work is warranted to
look at the effect of neuraminidase inhibitors on reso-
lution of symptoms and the effectiveness within the first
48 h of treatment.
Finally unlike Brendish et al., (2017) this study used an
influenza virus/RSV POCT rather than syndromic mul-
tiple for respiratory viruses [10]. The added value for
syndromic multiplex molecular POCT above molecular
Influenza virus testing is currently unknown but there
are potential clinical benefits to the detection of other
non-influenza viruses at the POCT including infection
control and early cessation of stopping unnecessary anti-
biotics, although these would need to be considered
against the extra expense of the syndromic panels.
Limitations of the study include the differences in In-
fluenza season in periods 1 and 2. There was a large dif-
ference in the amount of Influenza virus seen and a
difference in Influenza strains seen. This could have af-
fected the results observed and warrants further analysis
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in future Influenza seasons. Another factor to explain
the results seen is that the acuity of the strains of influ-
enza could potentially have been less virulent in the
current study. However, despite the limitations the qual-
ity and efficiency of management of influenza-like illness
was improved in season 2. To note there were no other
interventions during these two periods 1 and 2.
Conclusion
In conclusion, following the introduction of the POCT
at QEHB, there was an increase in appropriately targeted
oseltamivir prescribing, shorter time to isolation, propor-
tionally less 72-h influenza virus cases and a reduction
in length of stay of patients presenting with influenza-
like illness. This study demonstrates that POCTs have
the potential to improve the quality and efficiency of the
management of influenza-like illness. Although difficult
to quantify, there may be an additional benefit of admis-
sion avoidance. As per Brendish et al., (2017) influenza
virus POCT seems to be associated with health eco-
nomic benefit [10]. Routine use of POCTs for viruses
should be introduced into diagnostic pathways for acute
respiratory illness, especially at the front door of
hospitals.
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